Physician profile
Bret J Langenberg
NPI 1720014038
$3,064.34
in general payments reported to CMS, 2019-2025
38 companies · $645 in 2025
The $645 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $408 · 2021: $390 · 2022: $178 · 2023: $216 · 2024: $895 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225 · Long Term Medical Supply Or Device Loan: $531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.64 |
| Long Term Medical Supply Or Device Loan | $531.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $740.74 | 2019-2025 | Integra, Acell, Integra Dermal Regeneration Template |
| Intuitive Surgical, INC. | $292.14 | 2019-2025 | |
| Davol INC. | $209.26 | 2019-2023 | Phasix Mesh |
| Takeda Pharmaceuticals U.S.A., INC. | $196.87 | 2021-2024 | Gattex |
| Ethicon US, LLC | $181.34 | 2020-2025 | Surgicel Nu-Knit, Ethicon |
| Next Science LLC | $130.52 | 2021 | |
| Teleflex LLC | $89.04 | 2020-2025 | Deknatel |
| Abiomed | $84.44 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $78.62 | 2025 | |
| Becton, Dickinson and Company | $72.68 | 2024 | Arista Ah Flexitip |
| Alnylam Pharmaceuticals INC. | $68.74 | 2024-2025 | Amvuttra |
| Biotissue Holdings INC. | $65.88 | 2024-2025 | |
| Acera Surgical, INC. | $55.25 | 2023-2024 | Restrata Wound Matrix |
| Covidien LP | $53.61 | 2020 | |
| Innocoll Pharmaceuticals Limited | $52.63 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $51.47 | 2020-2022 | |
| Convatec INC. | $49.42 | 2020-2024 | |
| Medtronic, INC. | $40.62 | 2021-2025 | Dextile |
| Mallinckrodt Hospital Products INC. | $38.80 | 2024 | Acthar |
| Neurocrine Biosciences, INC. | $35.42 | 2024 | Ingrezza |
| Illuminoss Medical, INC. | $35.27 | 2024 | |
| Ucb, INC. | $34.90 | 2025 | Zilbrysq |
| Analogic Corporation | $32.65 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $31.43 | 2022 | |
| Wound Management Technologies, INC | $29.99 | 2019 | |
| Smith+Nephew, INC. | $29.81 | 2023 | Hat-Trick |
| Conmed Corporation | $29.79 | 2024 | Airseal |
| Tei Biosciences INC | $29.40 | 2019 | |
| Scpharmaceuticals INC. | $29.27 | 2024 | |
| Baxter Healthcare | $27.38 | 2019 | |
| Merck Sharp & Dohme LLC | $27.22 | 2024 | Verquvo |
| Aroa Biosurgery Incorporated | $26.49 | 2023 | |
| Misonix INC | $26.40 | 2021 | |
| Lifenet Health | $21.73 | 2023 | |
| Irhythm Technologies, INC. | $19.11 | 2024 | Zio Xt Patch, Zio Monitor |
| Checkpoint Surgical, INC | $18.45 | 2019 | |
| Mallinckrodt Enterprises LLC | $14.89 | 2019 | |
| Boston Scientific Corporation | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bret Langenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.